Skip to main content

Table 6 Projected total and net clinical and cost outcomes for 10 provinces in Canada

From: Modeling the impact of the difference in cross-protection data between a human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and a human papillomavirus (HPV)-6/11/16/18 vaccine in Canada

  Alberta British Columbia Manitoba New Brunswick Newfoundland Nova Scotia Ontario PEI Quebec Saskatchewan
Undiscounted lifetime cervical cancer cases
Vaccine A 223 71 23 8 6 11 269 2 208 11
Vaccine B 237 78 25 10 7 13 288 2 240 13
Difference (A- B) −14 −8 −2 −2 −1 −2 −19 0 −32 −2
Undiscounted short-term budget impact (CAD)
Vaccine A 8 862 430 3 431 536 1 071 737 1 039 079 673 843 1 244 617 11 758 847 173 180 14 284 003 1 426 186
Vaccine B 8 862 430 3 431 536 1 071 737 1 039 079 673 843 1 244 617 11 758 847 173 180 14 284 003 1 426 186
Difference (A-B) 0 0 0 0 0 0 0 0 0 0
Discounted long-term budget impact (CAD)
Vaccine A 71 372 551 15 984 442 4 131 005 2 865 649 1 858 981 3 600 539 48 811 638 491 961 58 240 107 3 861 885
Vaccine B 72 015 197 16 091 773 4 155 215 2 890 712 1 874 203 3 630 560 49 128 834 495 873 58 720 943 3 894 102
Difference (A-B) −642 645 −107 331 −24 210 −25 063 −15 222 −30 021 −317 196 −3 912 −480 836 −32 217
  1. Short-term budget impact: Considers 1 year of vaccine purchase and administration costs.
  2. Long-term budget impact: Considers lifetime costs to the health care system for the cohort of women eligible for vaccination in the 2011–12 school year. This includes both vaccinated and unvaccinated women.
  3. CAD - Canadian dollars.
  4. Vaccine A: HPV-16/18 AS04-adjuvanted vaccine.
  5. Vaccine B: HPV-6/11/16/18 vaccine.
  6. PEI – Prince Edward Island.